- Home
- ADIL vs CMMB Comparison
ADIL vs CMMB Comparison
Compare ADIL & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADIL | CMMB |
|---|---|---|
| Founded | 2010 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 10.2M |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ADIL | CMMB |
|---|---|---|
| Price | $4.22 | $1.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $8.33 | ★ $15.00 |
| AVG Volume (30 Days) | 34.3K | ★ 105.9K |
| Earning Date | 11-12-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $29.38 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $1.05 |
| 52 Week High | $9.53 | $3.44 |
Technical Indicators
Market Signals| Indicator | ADIL | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 25.00 |
| Support Level | $3.80 | $1.05 |
| Resistance Level | $4.94 | $1.89 |
| Average True Range (ATR) | 0.37 | 0.11 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 77.33 | 10.72 |
Price Performance
Historical ComparisonAbout ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.